Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy - PubMed (original) (raw)

Review

Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy

Subramanian Selvamuthukumar et al. Lipids Health Dis. 2012.

Abstract

Nanotechnology having developed exponentially, the aim has been on therapeutic undertaking, particularly for cancerous disease chemotherapy. Nanostructured lipid carriers have attracted expanding scientific and commercial vigilance in the last couple of years as alternate carriers for the pharmaceutical consignment, particularly anticancer pharmaceuticals. Shortcomings often came across with anticancer mixtures, such as poor solubility, normal tissue toxicity, poor specificity and steadiness, as well as the high incidence rate of pharmaceutical resistance and the rapid degradation, need of large-scale output procedures, a fast release of the pharmaceutical from its carrier scheme, steadiness troubles, the residues of the organic solvents utilized in the output method and the toxicity from the polymer with esteem to the carrier scheme are anticipated to be overcome through use of the Nanostructured Lipid Carrier. In this review the benefits, types, drug release modulations, steadiness and output techniques of NLCs are discussed. In supplement, the function of NLC in cancer chemotherapy is presented and hotspots in research are emphasized. It is foreseen that, in the beside future, nanostructured lipid carriers will be further advanced to consign cytotoxic anticancer compounds in a more efficient, exact and protected manner.

PubMed Disclaimer

Figures

Figure 1

Figure 1

SLN with high crystallinity and Different types of NLC. I – Highly imperfect matrix, II – Multiple O/F/W type, III – non-crystalline amorphous NLC.

Figure 2

Figure 2

Triggered pharmaceutical releases from NLC by starting the alteration from a highly disorganized lipid structure to more organized stable modifications.

Figure 3

Figure 3

Aggregation method in reduced intensified dispersions (upper) and pearl-like network in NLC dispersions with stabilizing effect.

Figure 4

Figure 4

Output of NLC Nanosuspension.

Similar articles

Cited by

References

    1. Barratt GM. Therapeutic applications of colloidal drug carriers. Pharm Sci Technolo Today. 2000;3:163–171. doi: 10.1016/S1461-5347(00)00255-8. - DOI - PubMed
    1. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196. doi: 10.1016/S0169-409X(01)00105-3. - DOI - PubMed
    1. Mainardes RM, Silva LP. Drug delivery systems: past, present, and future. Curr Drug Targets. 2004;5:449–455. doi: 10.2174/1389450043345407. - DOI - PubMed
    1. Gregoriadis G, Florence AT, Patel HM. In: Drug Targeting and Delivery. Florence AT, Chur GG, editor. Harwood Academic Publishers GmbH; 1993. Liposomes in drug delivery.
    1. Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol. 2005;18:209–219. doi: 10.1159/000086666. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources